5 questions answered from cited research · Plain language
Yes, complement pathways — especially the classical and alternative pathways — contribute to kidney injury in lupus nephritis by driving inflammation and tissue damage after immune complex deposition.
Read the full answer →Yes, the rs80213143 variant in LOC100130476 is linked to lupus nephritis risk in Chinese Han populations, with the C allele associated with more severe kidney involvement.
Read the full answer →Lysosomal pathways act as checkpoints that regulate immune activation, autoantigen processing, and metabolic-immune crosstalk, driving lupus nephritis progression.
Read the full answer →Yes, the CYP2C19*2 variant is linked to reduced cyclophosphamide toxicity in lupus nephritis, based on a meta-analysis showing a protective effect.
Read the full answer →Belimumab is approved for lupus nephritis and appears more effective than anifrolumab, which is not yet approved for this condition.
Read the full answer →